 Bicalutamide is an arylpropionamide analog, seen in figure 6.It has replaced flutamide and nilutamide as the first choice antiandrogen for prostate cancer treatment.Bicalutamide is not as hepatotoxic as flutamide and nilutamide and has a longer half-life, of 6 days in humans, that allows once a day administration at lower dosage.